Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756809 | 0.91 | LRRK2 (0.53) | LRRK2JAK2PDGFRBCCNA2CDK2 | |
| SCHEMBL13756839 | 0.83 | JAK2 (0.55) | LRRK2JAK2MKNK2CCNA2CDK2 | |
| SCHEMBL13756776 | 0.82 | PDGFRB (0.52) | JAK2PDGFRBCCNA2CDK2 | |
| SCHEMBL1654515 | 0.81 | PTK2 (0.59) | LRRK2JAK2MAP3K9MKNK2PDGFRB | |
| SCHEMBL13756842 | 0.80 | NUAK1 (0.45) | LRRK2JAK2CCNA2CDK2 | |
| SCHEMBL13756773 | 0.79 | EGFR (0.49) | LRRK2JAK2PKMYT1 | |
| SCHEMBL13756766 | 0.77 | NTRK1 (0.49) | LRRK2JAK2CCNA2CDK2 | |
| SCHEMBL13756837 | 0.75 | CDK2 (0.56) | LRRK2JAK2PDGFRBCCNA2CDK2 | |
| SCHEMBL13756838 | 0.75 | GRM5 (0.53) | LRRK2JAK2CCNA2CDK2 | |
| SCHEMBL13756697 | 0.75 | CSF1R (0.41) | LRRK2JAK2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | LRRK2 440/4885JAK2 2/4885MAP3K9 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.